Mozobil FDA Approval History
FDA Approved: Yes (First approved December 15, 2008)
Brand name: Mozobil
Generic name: plerixafor
Company: Genzyme Corporation
Treatment for: Bone Marrow Transplantation
Mozobil (plerixafor) is a small molecule CXCR4 chemokine receptor antagonist used in combination with granulocyte-colony stimulating factor to mobilize hematopoietic stem cells to the bloodstream for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma and multiple myeloma.
Development timeline for Mozobil
| Date | Article |
|---|---|
| Dec 16, 2008 | Approval FDA Approves Genzyme's Mozobil |
| Sep 23, 2008 | Genzyme Announces FDA Priority Review for Mozobil New Drug Application |
| Jun 17, 2008 | Genzyme Files Applications for Approval of Mozobil in the United States and Europe |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
